Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Tania Small"'
Autor:
Hela Romdhani, Annie Guerin, Debbie Goldschmidt, Sneha S. Kelkar, Patrick Gagnon-Sanschagrin, Eric Q. Wu, Anand A. Dalal, Tania Small, Polly A. Niravath, Geneviève Gauthier
Publikováno v:
Advances in Therapy. 35:1251-1264
In the treatment of metastatic breast cancer (mBC), regular monitoring is key in helping physicians to make informed clinical decisions, managing treatment side effects, and maintaining patients’ quality of life. Therefore, we investigated the moni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f066100d1da7cb01b9037046ce0585b4
https://doi.org/10.1007/s12325-018-0740-y
https://doi.org/10.1007/s12325-018-0740-y
Autor:
Anand A. Dalal, Annie Guerin, Patrick Gagnon-Sanschagrin, Tania Small, Geneviève Gauthier, Rebecca Burne, Polly A. Niravath
Publikováno v:
Advances in Therapy. 35:768-778
Targeted therapies have revolutionized the treatment of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer (mBC). However, as for many oncology drugs, the dose of targeted therapies may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7b2418db3ff574f6ef2420d5d51056e
https://doi.org/10.1007/s12325-018-0701-5
https://doi.org/10.1007/s12325-018-0701-5
Autor:
Anand A. Dalal, Deborah Goldschmidt, Eric Q. Wu, Hela Romdhani, Annie Guerin, Polly A. Niravath, Tania Small, Geneviève Gauthier, Sneha S. Kelkar
Publikováno v:
Advances in Therapy. 35:482-493
Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) metastatic breast cancer (mBC). The objective of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640dca5ed24f59ab276f8566b3fceaf9
https://doi.org/10.1007/s12325-018-0676-2
https://doi.org/10.1007/s12325-018-0676-2
Autor:
S Petrone, K Schutta, K Saintil, J Marsano-Feeley, K Waltman-Johnson, J Meyer, E Spatz Caplan, Tania Small, Das Purkayastha, N Bugazia, T Grasso, Wong Connie C, Alberto Ocana Fernandez, K Feldman
Publikováno v:
Cancer Research. 78:P4-10
Background: Reported 10-year survival rates in Caucasian, black, and Hispanic women with breast cancer are 80%, 66%, and 78%, respectively. One barrier to understanding disparities in these survival rates is the lack of data due to underrepresentatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bb6212a403e9cee0e4b0b895ed26ed7
https://doi.org/10.1158/1538-7445.sabcs17-p4-10-07
https://doi.org/10.1158/1538-7445.sabcs17-p4-10-07
Autor:
Tania Small, Polly A. Niravath, Annie Guerin, G Gauthier, Rebecca Burne, P Gagnon-Sanschagrin, AA Dalal
Publikováno v:
Cancer Research. 78:P5-20
Background: Dose modification related to adverse event is common in the treatment of metastatic breast cancer (mBC). Based on the dosage form and strengths available, dose modification may lead to drug wastage when the dose cannot be split or saved f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::639f12a4df940e6a70a39124d7b4c9cd
https://doi.org/10.1158/1538-7445.sabcs17-p5-20-15
https://doi.org/10.1158/1538-7445.sabcs17-p5-20-15
Autor:
Donald A. Richards, Lowell L. Hart, Sara M. Tolaney, M. Miller, D. A. Yardley, Paul Richards, JT Beck, Tania Small, Bhuvaneswari Ramaswamy, Gabriel N. Hortobagyi, Michaela Tsai, Francisco J. Esteva, Sibel Blau, Sami Diab, Joseph A. Sparano, Timothy J. Pluard, Das Purkayastha, Patrick S. Ward, A.M. Favret
Publikováno v:
Cancer Research. 78:P5-21
Background: Endocrine-based therapy is the standard of care for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), in whom delaying disease progression is the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2c4c4e065d4609600257188cd262a76
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-27
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-27
Autor:
Denise A. Yardley, R Dichmann, Cynthia X. Ma, Tania Small, C Tucci, Elizabeth Tan-Chiu, Tara Sanft, Amelia Zelnak, Stacy L. Moulder, Sibel Blau, Aditya Bardia, Amy S. Clark, Das Purkayastha, Lowell L. Hart, Gail S. Wright, Tanay S. Samant, AM DeMichele, Sara A. Hurvitz, Meghan Sri Karuturi, RL Moroose
Publikováno v:
Cancer Research. 78:PD5-11
This abstract was not presented at the symposium.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68fba9652471c411c60e7a58f33551dd
https://doi.org/10.1158/1538-7445.sabcs17-pd5-11
https://doi.org/10.1158/1538-7445.sabcs17-pd5-11
Autor:
Annie Guerin, Rebecca Burne, Patrick Gagnon-Sanschagrin, Anand A. Dalal, Tania Small, Polly A. Niravath, Geneviève Gauthier
Publikováno v:
Advances in therapy. 35(9)
Premenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (aBC) often present with aggressive tumor types that lead to poor prognosis, high rates of recurrence, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa283b222a08b68a1a4c467bbbf08e3
https://pubmed.ncbi.nlm.nih.gov/30105655
https://pubmed.ncbi.nlm.nih.gov/30105655
Autor:
Mitchell S. Cairo, Olga Militano, Tishi Shah, Carl V. Hamby, Carmella van de Ven, Mona Elmacken, Erin Morris, Janet Ayello, Sandra Fabricatore, Lauren Harrison, Tania Small, Aradhana Awasthi, Allyson Flower
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S196-S197
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98b08830fdd1e874c777911d3b5c4689
https://doi.org/10.1016/j.bbmt.2016.12.380
https://doi.org/10.1016/j.bbmt.2016.12.380
Autor:
Kamraan Z. Gill, Anthony N. Sireci, Govind Bhagat, Shafinaz Hussein, Vundavalli V. Murty, Tania Small, Foxwell Emmons, Adriana I. Colovai, Bachir Alobeid
Publikováno v:
British Journal of Haematology. 155:449-456
B lymphoblastic leukaemia (B-ALL) cells are characterized by the expression of various B-cell antigens. Expression of T/Natural Killer-cell antigens, however, has rarely been reported in B-ALL (TAg+ B-ALL), and the significance of this aberrant antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c27065e45df7b6b7912a4c2c1e23cd01
https://doi.org/10.1111/j.1365-2141.2011.08870.x
https://doi.org/10.1111/j.1365-2141.2011.08870.x